X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (627) 627
index medicus (583) 583
animals (388) 388
male (385) 385
female (374) 374
endonucleases - genetics (274) 274
middle aged (261) 261
oncology (261) 261
endonuclease (237) 237
aged (225) 225
endonucleases - metabolism (223) 223
dna-binding proteins - genetics (221) 221
adult (207) 207
antineoplastic combined chemotherapy protocols - therapeutic use (198) 198
mice (193) 193
apoptosis (159) 159
deoxyribonucleic acid--dna (157) 157
dna (157) 157
dna repair (156) 156
cancer (154) 154
chemotherapy (153) 153
cisplatin - administration & dosage (149) 149
dna-binding proteins - metabolism (147) 147
research (145) 145
cisplatin (139) 139
treatment outcome (136) 136
proteins (134) 134
prognosis (132) 132
multidisciplinary sciences (130) 130
ercc1 (129) 129
biochemistry & molecular biology (128) 128
dna damage (123) 123
gene expression (121) 121
genetic aspects (112) 112
lung neoplasms - drug therapy (112) 112
medicine (111) 111
research article (111) 111
genomes (110) 110
expression (108) 108
cell biology (104) 104
survival (102) 102
carcinoma, non-small-cell lung - drug therapy (101) 101
rats (100) 100
mutation (95) 95
analysis (93) 93
science (93) 93
dna-repair (89) 89
aged, 80 and over (86) 86
care and treatment (85) 85
genes (85) 85
immunohistochemistry (84) 84
neoplasm staging (82) 82
disease-free survival (80) 80
nucleases (80) 80
article (78) 78
genetics (78) 78
deoxyribonucleic acid (76) 76
health aspects (76) 76
enzymes (75) 75
genetics & heredity (75) 75
pharmacology & pharmacy (75) 75
biochemistry (74) 74
crispr (71) 71
apoptosis - drug effects (70) 70
biology and life sciences (70) 70
biology (69) 69
lung neoplasms - pathology (67) 67
cell lung-cancer (66) 66
lung neoplasms - genetics (66) 66
cell line, tumor (64) 64
medicine, research & experimental (64) 64
molecular biology (64) 64
carcinoma, non-small-cell lung - pathology (63) 63
biotechnology & applied microbiology (62) 62
polymorphism, single nucleotide (60) 60
retrospective studies (60) 60
carcinoma, non-small-cell lung - genetics (59) 59
organoplatinum compounds - administration & dosage (59) 59
fluorouracil - administration & dosage (58) 58
rna (58) 58
dna fragmentation (57) 57
cells (56) 56
deoxycytidine - analogs & derivatives (56) 56
nucleotide excision-repair (56) 56
activation (55) 55
base sequence (55) 55
repair (55) 55
research and analysis methods (55) 55
survival rate (55) 55
resistance (54) 54
deoxycytidine - administration & dosage (53) 53
genomics (53) 53
endonucleases - biosynthesis (52) 52
messenger-rna levels (52) 52
physiological aspects (52) 52
dna-binding proteins - biosynthesis (51) 51
tumors (51) 51
oxidative stress (49) 49
biotechnology (48) 48
genotype (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1019) 1019
Chinese (9) 9
German (4) 4
Russian (3) 3
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 10, pp. 913 - 923
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2016, Volume 113, Issue 11, pp. 2868 - 2873
A central challenge to the development of protein-based therapeutics is the inefficiency of delivery of protein cargo across the mammalian cell membrane,... 
Protein delivery | Genome editing | CRISPR/Cas9 | Cre recombinase | Lipid nanoparticle | THERAPEUTICS | genome editing | COMBINATORIAL LIBRARY | VIVO | RNA | CELLS IN-VITRO | CAS9 PROTEIN | TRANSFECTION | MULTIDISCIPLINARY SCIENCES | CANCER-THERAPY | lipid nanoparticle | protein delivery | INTRACELLULAR DELIVERY | Endonucleases - genetics | Thalamus - metabolism | Nanoparticles - chemistry | Humans | Green Fluorescent Proteins - genetics | Structure-Activity Relationship | Recombinant Proteins - biosynthesis | Endosomes - metabolism | Drug Carriers | Luminescent Proteins - biosynthesis | RNA - genetics | Cholesterol - chemistry | Endocytosis | Lipids - chemistry | Integrases - administration & dosage | Endonucleases - administration & dosage | Recombination, Genetic | Nanoparticles - metabolism | Molecular Structure | Genes, Reporter | Genetic Engineering - methods | Bacterial Proteins - genetics | Genes, Synthetic | Ceramides - chemistry | Lipids - administration & dosage | Gene Knockout Techniques | Static Electricity | Nanoparticles - toxicity | Bacterial Proteins - administration & dosage | Animals | Hypothalamus - metabolism | Lipids - chemical synthesis | Green Fluorescent Proteins - biosynthesis | CRISPR-Cas Systems | Luminescent Proteins - genetics | Mice | Nanoparticles - administration & dosage | HeLa Cells | Integrases - genetics | Phosphatidylethanolamines - chemistry | Nanoparticles | Genetic aspects | Nucleotide sequencing | Lipid metabolism | Health aspects | Methods | DNA sequencing | CRISPR | Physical Sciences | Cas9
Journal Article
Gene Therapy, ISSN 0969-7128, 01/2013, Volume 20, Issue 1, pp. 35 - 42
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2014, Volume 32, Issue 18, pp. 1889 - 1894
Purpose In advanced urothelial cancer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) results in a high response... 
CELL LUNG-CANCER | PHASE-III TRIAL | ONCOLOGY | ERCC1 | MARKERS | ADVANCED BLADDER-CANCER | DNA-REPAIR | CARCINOMA | EXPRESSION | CHEMOTHERAPY | Immunohistochemistry | Recombinant Proteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Magnetic Resonance Imaging - methods | DNA-Binding Proteins - analysis | Male | Protective Agents - therapeutic use | Vinblastine - administration & dosage | Filgrastim | Cisplatin - administration & dosage | Urinary Bladder Neoplasms - diagnostic imaging | Vinblastine - adverse effects | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Female | Chemotherapy, Adjuvant | Doxorubicin - administration & dosage | Drug Administration Schedule | Polyethylene Glycols | Biomarkers, Tumor - analysis | Neoplasm Invasiveness | Kaplan-Meier Estimate | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Granulocyte Colony-Stimulating Factor - therapeutic use | Urinary Bladder Neoplasms - surgery | Radiography | Disease-Free Survival | Methotrexate - adverse effects | Cystectomy | Carcinoma, Transitional Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - chemistry | Carcinoma, Transitional Cell - drug therapy | Cisplatin - adverse effects | Methotrexate - administration & dosage | Aged | Urinary Bladder Neoplasms - chemistry | Carcinoma, Transitional Cell - surgery | Endonucleases - analysis | Neoplasm Staging | Carcinoma, Transitional Cell - diagnostic imaging | Doxorubicin - adverse effects | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2013, Volume 71, Issue 3, pp. 789 - 797
The combination of docetaxel, cisplatin, and S-1 (DCS) chemotherapy is expected to be a promising regimen for advanced gastric cancer. This study was performed... 
Neoadjuvant chemotherapy | Medicine & Public Health | DSC | Oncology | Cancer Research | Advanced resectable gastric cancer | Nucleotide excision repair | Pharmacology/Toxicology | ADJUVANT CHEMOTHERAPY | SURGERY | PERIOPERATIVE CHEMOTHERAPY | GASTROESOPHAGEAL ADENOCARCINOMA | FLUOROURACIL | TRIAL | THERAPY | ONCOLOGY | ERCC1 | PHARMACOLOGY & PHARMACY | EXPRESSION | CARCINOMA | Endonucleases - genetics | Endosonography | Follow-Up Studies | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Antineoplastic Agents - administration & dosage | Endonucleases - metabolism | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | DNA-Binding Proteins - metabolism | Antineoplastic Agents, Phytogenic - administration & dosage | Adult | Female | DNA Repair - drug effects | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Combined Modality Therapy | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | DNA-Binding Proteins - genetics | Taxoids - administration & dosage | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | Survival Analysis | Biomarkers | Tegafur - administration & dosage | Aged | Stomach Neoplasms - surgery | Drug Combinations | Immunohistochemistry | Antimitotic agents | Medical colleges | Chemotherapy | Nausea | Drug therapy, Combination | Antineoplastic agents | DNA repair | Stomach cancer | Cancer | Protein binding | Index Medicus | Dendritic cells | anorexia | Toxicity | DNA damage | Chemoresistance | Diarrhea | Disease control | Cisplatin | DNA-binding protein | Surgery | ERCC1 protein | Gastric cancer | Neutropenia | Tumors
Journal Article
British Journal of Cancer, ISSN 0007-0920, 12/2012, Volume 107, Issue 12, pp. 1950 - 1955
BACKGROUND: The updated randomised phase 2/3 FIRIS study demonstrated the noninferiority of IRIS (irinotecan and S-1) to FOLFIRI (irinotecan, folinic acid, and... 
DPD | metastatic colorectal cancer | National Cancer Institute | oxaliplatin | ERCC1 | STEM-CELLS | MARKER | FLUOROURACIL FAILURE | RANDOMIZED-TRIAL | EGFR | HETEROGENEITY | ONCOLOGY | GENE-EXPRESSION | IRINOTECAN | KRAS | MUTATIONS | Immunohistochemistry | Leucovorin - administration & dosage | Up-Regulation | Endonucleases - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | United States | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | National Cancer Institute (U.S.) | Male | Endonucleases - metabolism | RNA, Messenger - metabolism | DNA-Binding Proteins - metabolism | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Oxaliplatin | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Real-Time Polymerase Chain Reaction | Camptothecin - analogs & derivatives | Colorectal Neoplasms - enzymology | DNA Topoisomerases, Type I - metabolism | DNA Topoisomerases, Type I - genetics | Oxonic Acid - administration & dosage | DNA-Binding Proteins - genetics | Gene Expression Regulation, Enzymologic | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Tegafur - administration & dosage | Aged | Colorectal Neoplasms - pathology | Dihydrouracil Dehydrogenase (NADP) - metabolism | Dihydrouracil Dehydrogenase (NADP) - genetics | Drug Combinations | Translational Therapeutics
Journal Article
Vaccine, ISSN 0264-410X, 2009, Volume 28, Issue 4, pp. 965 - 969
Journal Article
Molecular Therapy, ISSN 1525-0016, 01/2011, Volume 19, Issue 1, pp. 181 - 187
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2013, Volume 108, Issue 8, pp. 1695 - 1703
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2007, Volume 25, Issue 10, pp. 1247 - 1254
Journal Article